Study Reveals Glucagon Receptors' Role in Renal Health Study Reveals Glucagon Receptors' Role in Renal Health
In findings with implications for future therapies in chronic kidney disease, mouse studies show a protective effect of glucagon receptor signaling in the kidney.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 28, 2024 Category: Consumer Health News Tags: Nephrology Source Type: news

Two years after initial rejection, Akebia ’s anemia drug finally gets FDA approval
The FDA approved the Cambridge biotech's drug vadadustat for the treatment of anemia due to chronic kidney disease in adults who have been receiving dialysis for at least three months. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 28, 2024 Category: Biotechnology Authors: Hannah Green Source Type: news

Rwanda: Kayonza Survey - 10 Percent of Patients With NCDs Unknowingly Have Chronic Kidney Disease
[New Times] A team of doctors and nurses from Rwinkwavu Hospital and Partners in Health collected blood and urine samples to study the occurrence of chronic kidney disease in 1,268 patients with hypertension, 1,189 with HIV, and 582 with other non-communicable diseases (NCDs) across two phases. The study revealed that more than 300 patients out of 3,039 tested positive for chronic kidney disease. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - March 26, 2024 Category: African Health Tags: Central Africa East Africa Health and Medicine Rwanda Source Type: news

How to keep your kidneys working well
Kidney damage can ’t be reversed, but there are lifestyle steps and treatments that can help keep chronic kidney disease in check. (Source: Washington Post: To Your Health)
Source: Washington Post: To Your Health - March 25, 2024 Category: Consumer Health News Authors: Ashley Abramson, Halle Levine Source Type: news

Systemic Inflammation Increases Risk for Chronic Kidney Disease
FRIDAY, March 22, 2024 -- Systemic inflammation is associated with an elevated risk for chronic kidney disease, according to a study published online Feb. 20 in Frontiers in Immunology. Xiaoxin Liu, from Tongji Medical College at the Huazhong... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 22, 2024 Category: Pharmaceuticals Source Type: news

Chronic kidney disease duration and suicide risk among maintenance hemodialysis patients in China - Wang X, Hao X, Ma M, Jiang W, Li B, Xu Y, Sun P.
BACKGROUND: Our aim was to investigate the relationship between chronic kidney disease (CKD) duration and suicide risk among maintenance hemodialysis patients in China. METHODS: Patients with end-stage renal disease (ESRD) who received MHD were enr... (Source: SafetyLit)
Source: SafetyLit - March 22, 2024 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

CKD Leaders Network Publishes New Thought Piece in Journal of Clinical Medicine
NEW YORK, March 21, 2024 /PRNewswire/ -- In support of National Kidney Month, CKD Leaders Network, a Kinetix Group Network of Excellence dedicated to defining and spreading a best practice model for population health-driven chronic kidney disease (CKD) management, announced its new... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - March 21, 2024 Category: Pharmaceuticals Source Type: news

Mayo Clinic Minute: High blood pressure hurts the kidneys
Hypertension, also known as high blood pressure, is a common problem that affects the body's arteries. If you have high blood pressure, the heart has to work harder to pump blood. In general, hypertension is a blood pressure reading of 130/80 or higher. Dr. Ivan Porter II, a Mayo Clinic nephrologist, says high blood pressure can lead to heart disease, stroke and other serious health problems, including chronic kidney disease. Watch: The Mayo Clinic Minute… (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 21, 2024 Category: Databases & Libraries Source Type: news

DR ELLIE CANNON: Are statins to blame for my kidney disease?
At a recent check-up I was informed that I had developed chronic kidney disease, a total shock. Could my statin and a blood-pressure pill have caused this problem? (Source: the Mail online | Health)
Source: the Mail online | Health - March 16, 2024 Category: Consumer Health News Source Type: news

EHR Alerts Trigger Primary Care Clinics to Improve Hypertension Care in CKD
(MedPage Today) -- A computerized clinical decision support (CDS) tool for primary care helped lower blood pressure (BP) in patients with chronic kidney disease (CKD) and uncontrolled hypertension, a cluster-randomized trial found. When primary... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - March 15, 2024 Category: Cardiology Source Type: news

Chart Flag Boosts BP Control in Kidney Patients Chart Flag Boosts BP Control in Kidney Patients
Clinical decision support systems could be a promising tool to help clinicians control hypertension in patients with chronic kidney disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 14, 2024 Category: Consumer Health News Tags: Family Medicine/Primary Care Source Type: news

Nigeria: Overcoming Barriers to Kidney Health in Nigeria - - World Kidney Day 2024
[Nigeria Health Watch] Salisu Hauwa, a 33-year-old woman in Gashau, a Local Government Area (LGA) in northern Yobe State, Nigeria was diagnosed with chronic kidney disease (CKD) at the Yobe State University Teaching Hospital (YSUTH) in Damaturu. This diagnosis came weeks after she had been experiencing headaches and continuous vomiting. According to her husband, Abubakar Mohammed, Hauwa's condition worsened, as she was constantly screaming, biting, and attempting to run away from the hospital leading some to believe that she (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - March 13, 2024 Category: African Health Tags: Health and Medicine Nigeria West Africa Source Type: news

Risk for Rapid Progression Explored in Patients With CKD Stage G3
WEDNESDAY, March 13, 2024 -- Individuals with incident chronic kidney disease (CKD) stage G3 have a 14.6 percent three-year risk for rapid progression, according to a study recently published in Nephrology Dialysis Transplantation.Anne H.S.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 13, 2024 Category: Pharmaceuticals Source Type: news

Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month threeZilebesiran added to a standard of care hypertension medication demonstrated an encouraging safety and tolerability profile in adults with mild to moderate uncontrolled hypertension, and results support the potential for twice-yearly dosingRoche and Alnylam have initiated the Phase II KARDIA-3 study in adults with uncontrolled hypertension at high cardiovascular riskKARDIA-2 study results will be presented as a late-breaking abstract in April at the 2024 American College of Ca...
Source: Roche Investor Update - March 5, 2024 Category: Pharmaceuticals Source Type: news

Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care
KARDIA-2 study met its primary endpoint, demonstrating clinically significant systolic blood pressure reductions in each treatment arm at month threeZilebesiran added to a standard of care hypertension medication demonstrated an encouraging safety and tolerability profile in adults with mild to moderate uncontrolled hypertension, and results support the potential for twice-yearly dosingRoche and Alnylam have initiated the Phase II KARDIA-3 study in adults with uncontrolled hypertension at high cardiovascular riskKARDIA-2 study results will be presented as a late-breaking abstract in April at the 2024 American College of Ca...
Source: Roche Media News - March 5, 2024 Category: Pharmaceuticals Source Type: news